key: cord-0898134-i16n54en authors: Galloway, James; Bukhari, Marwan title: COVID-19 and mortality in rare rheumatic diseases, a warning bell? date: 2021-02-05 journal: Rheumatology (Oxford) DOI: 10.1093/rheumatology/keaa889 sha: ec14167d3baa51317a54361c18ed96437f1debe9 doc_id: 898134 cord_uid: i16n54en nan Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) pandemic, there has been an explosion of research on the impact of COVID-19 in patients who have rheumatic diseases. A worldwide registry was set up [1] , as well as many smaller studies, all trying to answer the logical questions about COVID-19: (i) do patients with rheumatic disease have an increased chance of developing to the disease; (ii) if they develop COVID-19 do they have a worse outcome; and (iii) do medications used to treat the rheumatic diseases alter the chances of progressing to severe respiratory disease? This latter aspect has placed patients with rheumatic disease under a spotlight, as there is a paradox: on one hand, immune modulation makes people theoretically more vulnerable to infection, but on the other, the very same treatments may protect against the inflammatory processes that underpin the development of severe COVID-19 disease. To date, most research has focused upon RA [2] [3] [4] . However, as rheumatologists, we support patients with a diverse spectrum of illnesses, many of which are fundamentally different from RA in terms of both immune disturbances attributable to the disease as well as the extent of immune modulation required for treatment. The impact of COVID-19 in these rarer diseases has received little attention so far. In the UK, the National Health Service (NHS) provides the majority of healthcare. The digital infrastructure was already being utilized to study epidemiological questions prior to COVID-19. Since March 2020, the teams working with the NHS have diverted their focus to the pandemic. In this edition of Rheumatology, we look at the research undertaken by Peach et al. [5] , who studied the mortality of COVID-19 in people with rare autoimmune rheumatic diseases, including GCA, SLE, JIA, inflammatory muscle diseases and vasculitides. The agestandardized mortality rates (ASMR) were compared between the rheumatic disease cohort and the general population for March and April 2020, as well as for the same calendar period in the preceding 5 years. The findings are in contrast to studies that have predominantly reflected inflammatory arthritis cohorts. The ASMR in the rare autoimmune rheumatic disease cohort was 3.7/100 compared with 1.4/100 in the general population, a difference that was much greater than anything observed in the previous 5 years. The analysis also considered differences across ages, demonstrating that the risk of COVID-19 mortality started climbing in patients aged 35 years and over, compared with the general population, where risks did not start to rise until above the age of 55 years. Gender did not emerge as a predictor of outcomes in the analysis, which is in contrast to the general population, where male gender is associated with worse outcomes. The results are important for the rheumatology community. This is the first report in a large population that shows a subpopulation under our care with increased mortality; second, it shows that risk factors for death are different, with no gender differences and an increased risk of death emerging at a much younger age. Several things must be taken into consideration. Firstly, is this a robust result? One of the key issues relates to the veracity of the diagnostic coding for the diseases in question. The group provide reassurance on this, with information on a subcohort of 740 patients, spread across the disease groups, that demonstrates a positive predictive value for the diagnoses of 85.6%. Secondly, it is important to acknowledge the diagnostic heterogeneity of the groups studied. GCA and JIA are two vastly different diseases. Future work by the authors plans to explore individual diagnoses further, although it is relevant to observe that the increased ASMR in the rheumatic disease cohorts extends into younger age groups, well below thresholds often quoted by the media as the 'safe' age. Finally, as the authors acknowledge, it is unclear whether the increase in mortality is directly attributable to COVID-19 infections or due to other factors such as reduced access to routine care. Again, looking to the future, we anticipate that linkage with other NHS datasets will permit such questions to be answered. The findings are important as they contradict the conclusions from the EULAR that there was 'no evidence that people with rheumatic musculoskeletal disorders face more risk of contracting SARS-CoV-2 than individuals without rheumatic musculoskeletal disorders, nor that they have a worse prognosis when they contract it' [6] . Similarly, data from OpenSAFELY [7] , a UK analysis of patient-level data from over 17 million people, reported no excess risks in rheumatic disease patients. The reason for the differences relates to the study populations. The studies to date have been heavily skewed towards people with inflammatory arthritis such as RA. The latest research from Peach et al. shines a light on a subgroup of patients with autoimmune rheumatic diseases that we manage with more aggressive immune modulatory strategies. The findings are relevant to clinicians in primary and secondary care, as well as policy makers. Advice on shielding and avoiding contact with the virus could take heed of this finding. Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry COVID-19 infection and rheumatoid arthritis: faraway, so close! Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Factors associated with COVID-19-related death using OpenSAFELY Funding: None.